Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models

Molecular Medicine Reports

Volumn 7, Issue 5, 2013, Pages 1470-1476

  Liang, Rui ^a   Zhang, Wei ^a   Song, Ya Mei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Interleukin 6; Leptin

Indexed keywords

INTERLEUKIN 6; LEPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYANOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXUDATE; HISTOLOGY; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEUKOCYTE COUNT; LUNG ALVEOLUS CELL; LUNG ALVEOLUS WALL; LUNG FUNCTION; LYMPHOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NONHUMAN; OUTPATIENT; PASSIVE SMOKING; PATHOGENESIS; PHYSICAL EXAMINATION; PROTEIN EXPRESSION; RAT; TACHYPNEA; VENOUS BLOOD; WEIGHT GAIN; WHEEZING;

ADULT; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LEPTIN; LUNG; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; SPUTUM;

RATTUS;

EID: 84875991026     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1377     Document Type: Article

References (30)

1. Vogelmeier C, Hederer B, Glaab T, et al: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364: 1093-1103, 2011.
2. Calverley PM, Anderson JA, Celli B, et al: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789, 2007.
3. Struik FM, Duiverman ML, Bladder G and Wijkstra PJ: Effects of non-invasive positive pressure ventilation (NIPPV) in stable chronic obstructive pulmonary disease (COPD). Respir Med COPD update 4: 94-100, 2008.
4. Murray CJ and Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504, 1997.
5. Fang X, Wang X and Bai C: COPD in China: the burden and importance of proper management. Chest 139: 920-929, 2011.
6. Yoon HI and Sin DD: Confronting the colossal crisis of COPD in China. Chest 139: 735-736, 2011.
7. Siafakas NM, Vermeire P, Pride NB, et al: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 8: 1398-1420, 1995.
8. de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH and Hiemstra PS: Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 190: 619-626, 2000.
9. Lewis MI and Belman MJ: Nutrition and the respiratory muscles. Clin Chest Med 9: 337-348, 1988.
10. Nishimura Y, Tsutsumi M, Nakata H, Tsunenari T, Maeda H and Yokoyama M: Relationship between respiratory muscle strength and lean body mass in men with COPD. Chest 107: 1232-1236, 1995.
11. Wouters EF, Groenewegen KH, Dentener MA and Vernooy JH: Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 4: 626-634, 2007.
12. Broekhuizen R, Vernooy JH, Schols AM, Dentener MA and Wouters EF: Leptin as local inflammatory marker in COPD. Respir Med 99: 70-74, 2005.
13. Auwerx J and Staels B: Leptin. Lancet 351: 737-742, 1998.
14. Yang YM, Sun TY and Liu XM: The role of serum leptin and tumor necrosis factor-alpha in malnutrition of male chronic obstructive pulmonary disease patients. Chin Med J (Engl) 119: 628-633, 2006.
15. Lam QL and Lu L: Role of leptin in immunity. Cell Mol Immunol 4: 1-13, 2007.
16. Bellmeyer A, Martino JM, Chandel NS, et al: Leptin resistance protects mice from hyperoxia-induced acute lung injury. Am J Respir Crit Care Med 175: 587-594, 2007.
17. Otero M, Lago R, Lago F, et al: Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579: 295-301, 2005.
18. Vernooy JH, Drummen NE, van Suylen RJ, et al: Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers. Thorax 64: 26-32, 2009.
19. Meier U and Gressner AM: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50: 1511-1525, 2004.
20. Sevenoaks MJ and Stockley RA: Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 7: 70, 2006.
21. Schols AM, Creutzberg EC, Buurman WA, et al: Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160: 1220-1226, 1999.
22. Bai XL and Xu JY: Smoking to rat blood lean meat, adiponectin, IL-6 and c-reactive protein influence. Chin J Respir Crit Care Med 9: 298-299, 2010 (In Chinese).
23. Sull JW, Kim HJ, Yun JE, et al: Serum adiponectin is associated with smoking status in healthy Korean men. Endocr J 56: 73-78, 2009.
24. Trujillo ME, Sullivan S, Harten I, et al: Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 89: 5577-5582, 2004.
25. Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115: 911-919, quiz 920, 2005.
26. Rose-John S, Waetzig GH, Scheller J, et al: The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11: 613-624, 2007.
27. Yanbaeva DG, Dentener MA, Creutzberg EC and Wouters EF: Systemic inflammation in COPD: is genetic susceptibility a key factor? COPD 3: 51-61, 2006.
28. Wouters EF: Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 26-33, 2005.
29. Walter RE, Wilk JB, Larson MG, et al: Systemic inflammation and COPD: the Framingham Heart Study. Chest 133: 19-25, 2008.
30. Foschino Barbaro MP, Carpagnano GE, Spanevello A, et al: Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol 20: 753-763, 2007.